Casodex
FDA Expands Zytiga for Late-Stage Prostate Cancer »
"The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
The FDA initially appr"...
Read the FDA Expands Zytiga for Late-Stage Prostate Cancer article »
Casodex
OVERDOSE
Long-term clinical trials have been conducted with dosages up to 200 mg of CASODEX (bicalutamide) daily and these dosages have been well tolerated. A single dose of CASODEX (bicalutamide) that results in symptoms of an overdose considered to be life threatening has not been established.
There is no specific antidote; treatment of an overdose should be symptomatic.
In the management of an overdose with CASODEX (bicalutamide) , vomiting may be induced if the patient is alert. It should be remembered that, in this patient population, multiple drugs may have been taken. Dialysis is not likely to be helpful since CASODEX (bicalutamide) is highly protein bound and is extensively metabolized. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.
CONTRAINDICATIONS
Hypersensitivity
CASODEX (bicalutamide) is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet's components. Hypersensitivity reactions including angioneurotic edema and urticaria have been reported [see SIDE EFFECTS].
Women
CASODEX (bicalutamide) has no indication for women, and should not be used in this population.
Pregnancy
CASODEX (bicalutamide) may cause fetal harm when administered to a pregnant woman. CASODEX (bicalutamide) is contraindicated in women, including those who are or may become pregnant. There are no studies in pregnant women using CASODEX (bicalutamide) . If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be appraised of the potential hazard to the fetus [see Use in Specific Populations].
Last reviewed on RxList: 3/13/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Casodex Information
Casodex - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.






